Pasar al contenido principal

ANALISIS DE TRANSCRIPTOMAS EN MODELOS DE ENFERMEDADES NEURODEGENERATIVAS PARA EL DISEÑO DE ESTRATEGIAS PALIATIVAS

SAF2011-22506

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2011
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CREB regulates distinct adaptive transcriptional programs in astrocytes and neurons

  • Pardo, Luis A.
  • Valor, Luis Miguel
  • Eraso-Pichot, Abel
  • Barco, Ángel
  • Golbano, Arantxa
  • Hardingham, Giles E.
  • Masgrau, Roser
  • Galea, Elena
The cyclic AMP response element binding protein (CREB) is a primary hub of activity-driven genetic programs in neurons controlling plasticity, neurogenesis and survival. By contrast, the gene networks coordinated by CREB in astrocytes are unknown despite the fact that the astrocytic CREB is also activity-driven and neuroprotective. Herein we identified the transcriptional programs regulated by CREB in astrocytes as compared to neurons using, as study materials, transcriptome databases of astrocyte exposed to well-known activators of CREB-dependent transcription as well as publicly available transcriptomes of neuronal cultures. Functional CREB signatures were extracted from the transcriptomes using Gene Ontology, adult-brain gene lists generated by Translating Ribosome Affinity Purification (TRAP) and CREB-target gene repositories. We found minimal overlap between CREB signatures in astrocytes and neurons. In astrocytes, the top triad of functions regulated by CREB consists of ‘Gene expression’, ‘Mitochondria’, and ‘Signalling’, while in neurons it is ‘Neurotransmission’, ‘Signalling’ and ‘Gene expression’, the latter two being represented by different genes from those in astrocytes. The newly generated databases will provide a tool to explore novel means whereby CREB impinges on brain functions requiring adaptive, long-lasting changes by coordinating transcriptional cascades in astrocytes., This work was supported by Ministerio de Economía y Competitividad, Spain (grant numbers BFU2012-38844 and BFU2016-79735-P to E.G.; SAF2011-22506 grant to L.M.V.; SAF2014-56197-R to A.B. an L.M.V.; PCIN-2015-192-C02-01 and SEV-2013-0317 to A.B.); Autonomous Government of Catalonia AGAUR (grant number 2014SGR984 to E.G. and R.M.); Generalitat Valenciana (grant number Prometeo/2012/005 to A.B.); and the Brain & Behavior Research Foundation (NARSAD Independent Investigator Grant) and the Alicia Koplovitz Foundation to A.B.). L.M.V. was additionally supported by a Ramón y Cajal contract (Ministerio de Economía y Competitividad), followed by a Miguel Servet contract (Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, and Fondo Social Europeo 2014–2020). The Instituto de Neurociencias de Alicante is a “Centre of Excellence Severo Ochoa”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Early alteration of epigenetic-related transcription in Huntington's disease mouse models

  • Hervás-Corpión, Irati
  • Guiretti, Deisy
  • Alcaraz-Iborra, Manuel
  • Olivares, Román
  • Campos-Caro, Antonio
  • Barco, Ángel
  • Valor, Luis Miguel
Transcriptional dysregulation in Huntington’s disease (HD) affects the expression of genes involved in survival and neuronal functions throughout the progression of the pathology. In recent years, extensive research has focused on epigenetic and chromatin-modifying factors as a causative explanation for such dysregulation, offering attractive targets for pharmacological therapies. In this work, we extensively examined the gene expression profiles in the cortex, striatum, hippocampus and cerebellum of juvenile R6/1 and N171-82Q mice, models of rapidly progressive HD, to retrieve the early transcriptional signatures associated with this pathology. These profiles were largely consistent across HD datasets, contained tissular and neuronal-specific genes and showed significant correspondence with the transcriptional changes in mouse strains deficient for epigenetic regulatory genes. The most prominent cases were the conditional knockout of the lysine acetyltransferase CBP in post-mitotic forebrain neurons, the double knockout of the histone methyltransferases Ezh1 and Ezh2, components of the polycomb repressor complex 2 (PRC2), and the conditional mutants of the histone methyltransferases G9a (Ehmt2) and GLP (Ehmt1). Based on these observations, we propose that the neuronal epigenetic status is compromised in the prodromal stages of HD, leading to an altered transcriptional programme that is prominently involved in neuronal identity., This work was supported by the Ministerio de Economía y Competitividad, co-financed by Fondo Europeo de Desarrollo Regional (Grants SAF2011-22506, SAF2014-56197-R, PCIN-2015-192-C02-01 and SEV-2013-0317), Instituto de Salud Carlos III, co-financed by Fondo Europeo de Desarrollo Regional 2014–2020 (Grants CP15/00180, PI16/00722 and PI15/01147) and Generalitat Valenciana (PROMETEO/2016/006). L.M.V. was the recipient of a Miguel Servet I contract (CP15/00180, Instituto de Salud Carlos III and Fondo Social Europeo 2014–2020). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease

  • Valor, Luis Miguel
The study of epigenetics is providing novel insights about the functional and developmental complexity of the nervous system. In neuropathology, therapies aimed at correcting epigenetic dysregulation have been extensively documented in a large variety of models for neurodegenerative, neurodevelopmental and psychiatric disorders. Taking the treatment of Huntington's disease as a paradigm for the study of these ameliorative strategies, this review updates the main conclusions derived from the use of epigenetic drugs at the preclinical and clinical stages, including actions beyond epigenetics., I thank to the Spanish Ministry of Economy and Competitiveness for the economic support (Ramón y Cajal contract and grant SAF2011-22506). The Instituto de Neurociencias is a Center of Excellence Severo Ochoa., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Epigenetic factors in intellectual disability: the Rubinstein-Taybi syndrome as a paradigm of neurodevelopmental disorder with epigenetic origin

  • López-Atalaya, José P.
  • Valor, Luis Miguel
  • Barco, Ángel
The number of genetic syndromes associated with intellectual disability that are caused by mutations in genes encoding chromatin-modifying enzymes has sharply risen in the last decade. We discuss here a neurodevelopmental disorder, the Rubinstein–Taybi syndrome (RSTS), originated by mutations in the genes encoding the lysine acetyltransferases CBP and p300. We first describe clinical and genetic aspects of the syndrome to later focus on the insight provided by the research in animal models of this disease. These studies have not only clarified the molecular etiology of RSTS and helped to dissect the developmental and adult components of the syndrome but also contributed to outline some important connections between epigenetics and cognition. We finally discuss how this body of research has opened new venues for the therapeutic intervention of this currently untreatable disease and present some of the outstanding questions in the field. We believe that the progress in the understanding of this rare disorder also has important implications for other intellectual disability disorders that share an epigenetic origin., Authors' research is supported by Grants SAF2011-22855 and SAF2011-22506 from the Spanish Ministry of Science and Innovation and Prometeo/2012/005 from the Generalitat Valenciana. The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic landscape of transcriptional and epigenetic dysregulation in early onset polyglutamine disease

  • Valor, Luis Miguel
  • Guiretti, Deisy
  • López-Atalaya, José P.
  • Barco, Ángel
Transcriptional dysregulation is an important early feature of polyglutamine diseases. One of its proposed causes is defective neuronal histone acetylation, but important aspects of this hypothesis, such as the precise genomic topography of acetylation deficits and the relationship between transcriptional and acetylation alterations at the whole-genome level, remain unknown. The new techniques for the mapping of histone post-translational modifications at genomic scale enable such global analyses and are challenging some assumptions about the role of specific histone modifications in gene expression. We examined here the genome-wide correlation of histone acetylation and gene expression defects in a mouse model of early onset Huntington's disease. Our analyses identified hundreds of loci that were hypoacetylated for H3K9,14 and H4K12 in the chromatin of these mice. Surprisingly, few genes with altered transcript levels in mutant mice showed significant changes in these acetylation marks and vice versa. Our screen, however, identified a subset of genes in which H3K9,14 deacetylation and transcriptional dysregulation concur. Genes in this group were consistently affected in different brain areas, mouse models, and tissue from patients, which suggests a role in the etiology of this pathology. Overall, the combination of histone acetylation and gene expression screenings demonstrates that histone deacetylation and transcriptional dysregulation are two early, largely independent, manifestations of polyglutamine disease and suggests that additional epigenetic marks or mechanisms are required for explaining the full range of transcriptional alterations associated with this disorder., This work was supported by the Spanish Ministry of Science and Innovation (Grants SAF2008-03194-E (part of the coordinated ERA-Net NEURON project Epitherapy) and SAF2011-22855 to A.B., SAF2011-22506 to L.M.V., and CSD2007-00023) and grants from the Generalitat Valenciana (Prometeo/2012/005), Fundació La Marató de TV3 (063510) and Fundació Gent per Gent. We thank the support of Asociación Valenciana de Enfermedad de Huntington (AVAEH). L.M.V.'s research is supported by a Ramón y Cajal contract from the Spanish Ministry of Economy and Competiveness. D.G. and J.P.L.-A. hold, respectively, a predoctoral fellowship (JAE-pre) and a postdoctoral contract (JAE-doc) from the Program “Junta para la Ampliación de Estudios” cofunded by the Fondo Social Europeo (FSE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition

  • López-Atalaya, José P.
  • Ito, Satomi
  • Valor, Luis Miguel
  • Benito, Eva
  • Barco, Ángel
Histone deacetylase inhibitors (HDACis) have been shown to potentiate hippocampal-dependent memory and synaptic plasticity and to ameliorate cognitive deficits and degeneration in animal models for different neuropsychiatric conditions. However, the impact of these drugs on hippocampal histone acetylation and gene expression profiles at the genomic level, and the molecular mechanisms that underlie their specificity and beneficial effects in neural tissue, remains obscure. Here, we mapped four relevant histone marks (H3K4me3, AcH3K9,14, AcH4K12 and pan-AcH2B) in hippocampal chromatin and investigated at the whole-genome level the impact of HDAC inhibition on acetylation profiles and basal and activity-driven gene expression. HDAC inhibition caused a dramatic histone hyperacetylation that was largely restricted to active loci pre-marked with H3K4me3 and AcH3K9,14. In addition, the comparison of Chromatin immunoprecipitation sequencing and gene expression profiles indicated that Trichostatin A-induced histone hyperacetylation, like histone hypoacetylation induced by histone acetyltransferase deficiency, had a modest impact on hippocampal gene expression and did not affect the transient transcriptional response to novelty exposure. However, HDAC inhibition caused the rapid induction of a homeostatic gene program related to chromatin deacetylation. These results illuminate both the relationship between hippocampal gene expression and histone acetylation and the mechanism of action of these important neuropsychiatric drugs., J.L.A. holds a postdoctoral contract (JAE-doc) from the Program ‘Junta para la Ampliación de Estudios’ co-funded by the Fondo Social Europeo (FSE). S.I. holds a Juan de la Cierva contract from the Spanish Ministry of Economy and Competitiveness. L.M.V. holds a Ramón y Cajal contract from the Spanish Ministry of Economy and Competitiveness. [CSD2007-00023, SAF2008-03194-E] (part of the coordinated ERA-Net NEURON project Epitherapy), [SAF2011-22855 and SAF2011-22506 to L.M.V.], Spanish Ministry of Economy and Competitiveness; [Prometeo/2012/005] Generalitat Valenciana; and the Fundació Gent per Gent., Funding for open access charge: Spanish Ministry of Economy and Competitiveness., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders

  • Valor, Luis Miguel
  • Viosca, José
  • López-Atalaya, José P.
  • Barco, Ángel
Neuropsychiatric pathologies, including neurodegenerative diseases and neurodevelopmental syndromes, are frequently associated with dysregulation of various essential cellular mechanisms, such as transcription, mitochondrial respiration and protein degradation. In these complex scenarios, it is difficult to pinpoint the specific molecular dysfunction that initiated the pathology or that led to the fatal cascade of events that ends with the death of the neuron. Among the possible original factors, epigenetic dysregulation has attracted special attention. This review focuses on two highly related epigenetic factors that are directly involved in a number of neurological disorders, the lysine acetyltransferases CREB-binding protein (CBP) and E1A-associated protein p300 (p300). We first comment on the role of chromatin acetylation and the enzymes that control it, particularly CBP and p300, in neuronal plasticity and cognition. Next, we describe the involvement of these proteins in intellectual disability and in different neurodegenerative diseases. Finally, we discuss the potential of ameliorative strategies targeting CBP/p300 for the treatment of these disorders., Research at Barco’s lab is supported by the grants SAF2008-03194-E (part of the coordinated ERA-Net NEURON project Epitherapy), SAF2011-22855 and CSD2007-00023 from the Spanish Ministry of Science and Innovation, the GVA Grant Prometeo/2012/005 and a grant from the Fundació Gent per Gent. LMV is supported by a Ramón y Cajal contract and the grant SAF2011-22506 from the Spanish Ministry of Economy and Competiveness. JLA holds a postdoctoral contract (JAE-doc) from the Program “Junta para la Ampliación de Estudios” co-funded by the Fondo Social Europeo (FSE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes

  • Guiretti, Deisy
  • Sempere, Ana
  • López-Atalaya, José P.
  • Ferrer-Montiel, Antonio
  • Barco, Ángel
  • Valor, Luis Miguel
Defective epigenetic regulation has been postulated as a possible cause for the extensive and premature transcriptional dysregulation observed in experimental models of Huntington's disease (HD). In this study, we extended our observations in the N171-82Q mouse strain relating to the limited impact of polyQ pathology on the global histone acetylation to other animal and cellular models of HD, namely the R6/1 and YAC128 strains, striatal-electroporated mice, primary neuronal cultures and stably transfected PC12 cells. In the absence of bulk chromatin changes, we nonetheless documented histone deacetylation events at the transcription start sites (TSS) of genes relevant to neuronal functions (e.g., Rin1, Plk5, Igfbp5, Eomes, and Fos). In some instances, these local deficits were associated with an increased susceptibility to transcriptional dysregulation (e.g., Camk1g and Rasl11b) and the defective trimethylation of histone H3 at lysine 4 (H3K4me3), another covalent modification of histone tails that is related to active transcription and is also altered in HD. Overall, this study provides further insight into the nature and extent of epigenetic dysregulation in HD pathology., This work was supported by the Spanish Ministry of Economy and Competitiveness (Grants SAF2011-22506, SAF2011-22855, BFU2012-39092-C02-01 and SAF2014-56197-R), the Fundació Gent per Gent (19-NEURO), Asociación Valenciana de Enfermedad de Huntington (AVAEH) and Generalitat Valenciana (Prometeo/2012/005, ISIC/2012/009 and Prometeo/2014/011). L.M.V.'s research is further supported by a Ramón y Cajal contract from the Spanish Ministry of Economy and Competitiveness. D.G. thanks the CSIC for a predoctoral fellowship (JAE-pre from the Programme “Junta para la Ampliación de Estudios”, which is co-funded by the Fondo Social Europeo (FSE)). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transcription, epigenetics and ameliorative strategies in huntington’s disease: A genome-wide perspective

  • Valor, Luis Miguel
This article is distributed under the terms of the Creative Commons Attribution License., Transcriptional dysregulation in Huntington's disease (HD) is an early event that shapes the brain transcriptome by both the depletion and ectopic activation of gene products that eventually affect survival and neuronal functions. Disruption in the activity of gene expression regulators, such as transcription factors, chromatin-remodeling proteins, and noncoding RNAs, accounts for the expression changes observed in multiple animal and cellular models of HD and in samples from patients. Here, I review the recent advances in the study of HD transcriptional dysregulation and its causes to finally discuss the possible implications in ameliorative strategies from a genome-wide perspective. To date, the use of genome-wide approaches, predominantly based on microarray platforms, has been successful in providing an extensive catalog of differentially regulated genes, including biomarkers aimed at monitoring the progress of the pathology. Although still incipient, the introduction of combined next-generation sequencing techniques is enhancing our comprehension of the mechanisms underlying altered transcriptional dysregulation in HD by providing the first genomic landscapes associated with epigenetics and the occupancy of transcription factors. In addition, the use of genome-wide approaches is becoming more and more necessary to evaluate the efficacy and safety of ameliorative strategies and to identify novel mechanisms of amelioration that may help in the improvement of current preclinical therapeutics. Finally, the major conclusions obtained from HD transcriptomics studies have the potential to be extrapolated to other neurodegenerative disorders., I thank the Spanish Ministry of Economy and Competitiveness for the economic support (Ramón Cajal contract and grant SAF2011-22506)., Peer reviewed